Vraylar (Cariprazine) Dosage, Indications, Interactions, Side Effects and More (2023)

  • Acrivastin

    Acrivastine and cariprazine increase sedation. Be careful / watch out.

  • Almotriptano

    almotriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Amifostine

    amifostine, cariprazine. Both potentiate the effects of the other by blocking the antihypertensive channel. Be careful / watch out. Because of their alpha-adrenergic antagonism, atypical antipsychotics have the potential to potentiate the effects of certain antihypertensive drugs. Monitor blood pressure and adjust dose accordingly.

  • amissulprida

    Amisulpride and cariprazine increase sedation. Be careful / watch out.

  • Mustard

    Asenapine and cariprazine increase sedation. Be careful / watch out.

  • asenapina transdermica

    Transdermal asenapine and cariprazine increase sedation. Be careful / watch out.

  • Atazanavir

    Atazanavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • in Belzutifa

    Belzutifan decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. If co-administration of belzutifan with sensitive CYP3A4 substrates cannot be avoided, consider increasing the dose of the sensitive CYP3A4 substrate according to the prescribing information.

  • Benazepril

    Cariprazine increases the toxicity of benazepril through pharmacodynamic synergism. Be careful / watch out. Increases the risk of hypotension.Benazepril increases the toxicity of cariprazine through pharmacodynamic synergism. Be careful / watch out. Increases the risk of hypotension.

  • Brexanolona

    brexanolone, cariprazine. Both increase the toxicity of the other through sedation. Be careful / watch out.

  • Buprenorphine long-acting injection

    Cariprazine increases the toxicity of long-acting buprenorphine for injection through pharmacodynamic synergism. Adjust/monitor therapy closely. Concomitant use of buprenorphine and benzodiazepines or other CNS depressants increases the risk of adverse events, including overdose, respiratory depression, and death. Discontinuation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher treatment level may be appropriate to reduce CNS depressant effects. In other cases, it may be appropriate to reduce the prescription of a benzodiazepine or other CNS depressant, or reduce it to the lowest effective dose.

  • Captopril

    cariprazine, captopril. Both potentiate the toxicity of the other through pharmacodynamic synergism. Be careful / watch out. Both drugs lower blood pressure. Monitor blood pressure.

  • Cenobamate

    cenobamate, cariprazine. Both potentiate the effect of the other through sedation. Be careful / watch out.

  • Clarithromycin

    Clarithromycin increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • kobischer Status

    Cobicistat increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • conivaptana

    Conivaptan increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • daridorexant

    Cariprazine and daridorexant increase sedation. Adjust/monitor therapy closely. Concomitant use increases the risk of CNS depression, which can lead to further impairment of psychomotor performance and impairment of time of day.

  • darunavir

    Darunavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • signrabenazina

    Cariprazine and deuterabenazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Adjust/monitor therapy closely. The risk of parkinsonism, neuroleptic malignant syndrome and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.Cariprazine and deutetrabenazine increase sedation. Be careful / watch out.

  • dextrometorfano

    dextromethorphan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • difelikefalin

    Difelikefalin and cariprazine increase sedation. Be careful / watch out.

  • Dihydroergotamin

    dihydroergotamine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • to take a bath

    Duvelisib increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. increases the level or effect of

  • Elagolix

    elagolix decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Elagolix is ​​a weak to moderate CYP3A4 inducer. Monitor CYP3A substrates when used concomitantly. If necessary, consider increasing the CYP3A substrate dose.

  • electricity

    eletriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Elvitegravir/Cobicistato/Emtricitabina/Tenofovir DF

    Elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Encorafenib

    encorafenib, cariprazine. affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Be careful / watch out. Encorafenib inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Co-administration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.

  • mesilatos ergoloides

    Ergoloid mesylate, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Ergotamine

    ergotamine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Escetamina intranasal

    intranasal esketamine, cariprazine. Both increase the toxicity of the other through sedation. Adjust/monitor therapy closely.

  • Federatinib

    Fedratinib increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out. Adjust the dose of drugs that are CYP3A4 substrates as needed.

  • Fenfluramin

    Cariprazine decreases the effect of fenfluramine through pharmacodynamic antagonism. Be careful / watch out. Strong serotonin receptor antagonists can reduce the effectiveness of fenfluramine. Monitor accordingly if used concomitantly.

  • Fentanyl

    fentanyl, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • flbans

    flibanserin, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Fosamprenavir

    Fosamprenavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Frovatriptan

    frovatriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • and be honest

    Cariprazine and ganaxolone increase sedation. Be careful / watch out.

  • Pampelmuse

    Grapefruit increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • ideally

    Idelalisib increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • imatinib

    Imatinib increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Indinavir

    Indinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Insulin resistant

    Cariprazine reduces the effect of insulin degludec by others (see comment). Be careful / watch out. Comment: Atypical antipsychotics have been associated with hyperglycemia, which can impair glycemic control; antidiabetic drug doses may need to be adjusted and more frequent glucose monitoring may be required.

  • Insulin degludeca/Insulin aspart

    Cariprazine reduces the effect of insulin degludec/insulin aspart by others (see comment). Be careful / watch out. Comment: Atypical antipsychotics have been associated with hyperglycemia, which can impair glycemic control; antidiabetic drug doses may need to be adjusted and more frequent glucose monitoring may be required.

  • Inhaled insulin

    Cariprazine decreases the effects of insulin inhaled by others (see comment). Be careful / watch out. Comment: Atypical antipsychotics have been associated with hyperglycemia, which can impair glycemic control; antidiabetic drug doses may need to be adjusted and more frequent glucose monitoring may be required.

  • Isoniazid

    Isoniazid increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • istradefilin

    Istradefylline increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Be careful / watch out. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical studies. This effect was not observed with istradefylline 20 mg/day. Consider reducing the dose of sensitive CYP3A4 substrates.

  • itraconazole

    Itraconazole increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Ketoconazole

    Ketoconazole increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • lasmiditano

    lasmiditan, cariprazine. Both potentiate the effect of the other through sedation. Be careful / watch out. The concomitant use of Lasmiditan and other CNS depressants, including alcohol, has not been studied in clinical studies. Lasmiditan can cause sedation as well as other cognitive and/or neuropsychiatric side effects.

  • Lemborexante

    lemborexant, cariprazine. Both potentiate the effect of the other through sedation. Adjust/monitor therapy closely. Dose adjustment may be required when lemborexant is co-administered with other CNS depressant medicinal products due to potential additive effects.

  • lenacapavir

    Lenacapavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates started within 9 months of the last subcutaneous lenacapavir dosing, which may increase the potential risk of CYP3A4 substrate adverse reactions.

  • Levocetoconazol

    Levoketoconazole increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Levomilnacipran

    Levomilnacipran, Cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Linezolid

    Linezolid, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Lithium

    lithium, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Lopinavir

    Lopinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • von Lorcaser

    lorcaserin, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Meperidina

    meperidine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Metformin

    Cariprazine decreases the effect of metformin through pharmacodynamic antagonism. Be careful / watch out.

  • methadone

    methadone, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Methylergonovina

    methylergonovine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • methylphenidate

    Cariprazine increases the toxicity of methylphenidate through pharmacodynamic antagonism. Be careful / watch out. When these drugs are used in combination, close monitoring should be done for evidence of an altered clinical response to methylphenidate or an antipsychotic.

  • Midazolam intranasal

    intranasal midazolam, cariprazine. Both potentiate the effects of the other through pharmacodynamic synergism. Adjust/monitor therapy closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and contribute to a potent and/or sustained drug effect.

  • Milnacipran

    Milnacipran, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Naratriptan

    Naratriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Nefazodon

    Nefazodone increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Nelfinavir

    Nelfinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Nicardipina

    Nicardipine increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Oliceridin

    oliceridine, cariprazine. Both potentiate the toxicity of the other through pharmacodynamic synergism. Adjust/monitor therapy closely. With concomitant use, severe sedation, respiratory depression, coma and death may occur. Reserve the concomitant prescription of these drugs for patients for whom other treatment options are unsuitable. Limit doses and duration to the minimum necessary. Pay close attention to signs of respiratory depression and sedation.

  • Paroxetine

    paroxetine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • fennel

    phenelzine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Posaconazol

    Posaconazole increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • procarbazina

    procarbazine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Promethazine

    promethazine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Chinidin

    Quinidine increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Remimazolam

    remimazolam, cariprazine. Both increase the toxicity of the other through sedation. Adjust/monitor therapy closely. Concomitant use may result in severe sedation, respiratory depression, coma and/or death. Vital signs should be continuously monitored during sedation and the recovery period, if administered simultaneously. Carefully titrate the dose of remizolam when co-administered with opioid analgesics and/or sedatives/hypnotics.

  • Ribocycline

    Ribociclib increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Be careful / watch out.

  • Ritonavir

    Ritonavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • rucaparibe

    Rucaparib increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Adjust the dose of CYP3A4 substrates when clinically indicated.

  • Saquinavir

    Saquinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Selegilina

    selegiline, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Sodium Sulphate/Magnesium Sulphate/Potassium Chloride

    Sodium sulfate/magnesium sulfate/potassium chloride potentiate the effects of cariprazine by an unknown mechanism. Be careful / watch out. Watch closely for signs of increased CNS depression when a higher dose of magnesium sulfate is used in conjunction with a CNS depressant.

  • Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate

    Sodium sulfate/potassium sulfate/magnesium sulfate potentiate the effects of cariprazine by an unknown mechanism. Be careful / watch out. Watch closely for signs of increased CNS depression when a higher dose of magnesium sulfate is used in conjunction with a CNS depressant.

  • Stiripentulus

    stiripentol, cariprazine. affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Stiripentol is an inhibitor and inducer of CYP3A4. Monitor CYP3A4 substrates co-administered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dose adjustment.stiripentol, cariprazine. Both potentiate the effect of the other through sedation. Be careful / watch out. Concomitant use of medicinal products with CNS depressant effects with thalidomide should be avoided due to the risk of additional sedative effects.

  • Sumatriptan

    sumatriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Sumatriptano intranasal

    intranasal sumatriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Tazemetostato

    Tazemetostat decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out.

  • Tecovirimat

    Tecovirimat decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out. Tecovirimate is a weak inducer of CYP3A4. Monitor the potency of sensitive CYP3A4 substrates when co-administered.

  • Tipranavir

    Tipranavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Tranylcypromin

    tranylcypromine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Venlafaxine

    venlafaxine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Vilazodona

    Vilazodone, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • Voriconazol

    Voriconazole increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.

  • Zolmitriptan

    Zolmitriptan, Cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).

  • References

    Top Articles
    Latest Posts
    Article information

    Author: Greg O'Connell

    Last Updated: 09/03/2023

    Views: 5607

    Rating: 4.1 / 5 (62 voted)

    Reviews: 93% of readers found this page helpful

    Author information

    Name: Greg O'Connell

    Birthday: 1992-01-10

    Address: Suite 517 2436 Jefferey Pass, Shanitaside, UT 27519

    Phone: +2614651609714

    Job: Education Developer

    Hobby: Cooking, Gambling, Pottery, Shooting, Baseball, Singing, Snowboarding

    Introduction: My name is Greg O'Connell, I am a delightful, colorful, talented, kind, lively, modern, tender person who loves writing and wants to share my knowledge and understanding with you.